Treatment Recommendations Developed for Nail Psoriasis

This article originally appeared here.
Share this content:
Treatment Recommendations Developed for Nail Psoriasis
Treatment Recommendations Developed for Nail Psoriasis

THURSDAY, Dec. 4, 2014 (HealthDay News) -- Treatment recommendations have been developed for patients with nail psoriasis. The recommendations were published online Dec. 3 in JAMA Dermatology.

Jeffrey J. Crowley, M.D., from Bakersfield Dermatology in California, and colleagues developed treatment guidelines for nail psoriasis. Based on evidence reviewed and the expert opinion of the Medical Board of the National Psoriasis Foundation, recommendations for four clinical nail psoriasis scenarios were developed.

The authors note that when treating nail psoriasis physicians should consider the extent of skin disease, psoriatic arthritis, and nail disease severity as well as quality-of-life impairment. Due to its potential for complicating psoriatic nail disease, all patients should be evaluated for onychomycosis. Initial options for disease limited to the nails include high-potency topical corticosteroids with or without calcipotriol. Treatment with adalimumab, etanercept, intralesional corticosteroids, ustekinumab, methotrexate sodium, and acitretin is recommended for patients with significant nail disease for whom topical therapy has failed. Adalimumab, etanercept, and ustekinumab are strongly recommended for patients with significant skin and nail disease; methotrexate, acitretin, infliximab, and apremilast are also recommended. Adalimumab, etanercept, ustekinumab, infliximab, methotrexate, apremilast, and golimumab are recommended for patients with significant nail, skin, and joint disease.

"Treatment of nail psoriasis poses a clinical challenge. Clinical trial data are limited, and results are reported inconsistently, making comparisons among treatment options difficult," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »